IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – Here’s Why

IPSEN (OTCMKTS:IPSEY) saw strong trading volume on Tuesday . 29,446 shares changed hands during mid-day trading, an increase of 450% from the previous session’s volume of 5,358 shares.The stock last traded at $38.45 and had previously closed at $39.10.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IPSEY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. BNP Paribas lowered IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. Finally, UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, IPSEN currently has a consensus rating of “Hold”.

IPSEN Stock Performance

The company has a 50-day moving average of $36.29 and a two-hundred day moving average of $34.29.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).